📄 medicine

Variant-selective RNA-targeting small molecules partially restore CFTR W1282X function in Cystic Fibrosis

This study demonstrates that structure-guided small molecules can selectively target a unique RNA conformation induced by the CFTR W1282X mutation to stabilize the transcript, thereby partially restoring CFTR function in cystic fibrosis cells.

Original authors: May Khanna, Niloofar Ghadirian, Elvia Rodriguez-Manriquez, Cecilia Pena-Rasgado, Satyam Killari, Wren Michaels, Samantha Perez-Miller, Jessica Centa, Bahaa Elgendy, Michelle L. Hastings

Published 2026-07-03

📖 5 min read🧠 Deep dive

CC BY 4.0

Original authors: May Khanna, Niloofar Ghadirian, Elvia Rodriguez-Manriquez, Cecilia Pena-Rasgado, Satyam Killari, Wren Michaels, Samantha Perez-Miller, Jessica Centa, Bahaa Elgendy, Michelle L. Hastings

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

The Big Picture: A Broken Instruction Manual

Imagine your body is a massive factory, and inside every cell, there is a master instruction manual (DNA) that tells the factory how to build a specific machine called CFTR. This machine acts like a gatekeeper, letting salt and water flow in and out of cells to keep your lungs and other organs clean and moist.

In people with Cystic Fibrosis (CF), this instruction manual has a typo. Specifically, in a section called "Exon 23," there is a single letter mistake (changing a G to an A). This typo creates a "Stop" sign way too early in the instructions.

Because of this early "Stop," the cell's quality control team (a process called NMD) sees the instructions as defective and immediately shreds the manual before the machine can even be built. This is why people with this specific mutation (W1282X) have very little of the CFTR machine, leading to the disease.

The Discovery: The Typo Changed the Shape of the Paper

The researchers asked a clever question: Does this single letter typo change the physical shape of the instruction manual, even before it gets shredded?

Usually, scientists look at the words (the sequence) to find problems. But this team looked at the folding (the shape).

The Wild-Type (Normal) Manual: When folded, this section of the paper is flat and open, like a smooth sheet of paper.
The W1282X (Mutant) Manual: Because of that single letter change, this section folds into a tight, distinct hairpin loop (like a paperclip shape) that the normal version doesn't have.

Crucially, the researchers found that this weird "hairpin" shape doesn't just happen in a test tube; it actually forms inside living human cells, too. It's a unique physical fingerprint that only the broken manual has.

The Solution: Finding a Key for a Unique Lock

For years, scientists have tried to fix CF by targeting the protein (the machine) or using giant tools (like ASOs) to skip the broken page. But the researchers wanted to try something new: targeting the RNA shape itself with a tiny chemical key.

Virtual Search: They used a computer to simulate millions of tiny chemical shapes (small molecules) to see which one would fit perfectly into that unique "hairpin" lock on the mutant manual.
The Winners: They found two candidates, named CTC20 and CTC24. Think of these as custom-made keys.
- CTC24 is the better key. It fits the mutant "hairpin" lock tightly but ignores the normal, flat paper. It is "variant-selective," meaning it only targets the broken instructions, not the healthy ones.

How It Works: Saving the Manual from the Shredder

When these tiny keys (CTC20 and CTC24) bind to the mutant RNA, they act like a stabilizer.

The Mechanism: By sticking to that specific hairpin shape, the small molecules seem to confuse the cell's "shredder" (NMD). The cell doesn't realize the manual is defective anymore, or at least it hesitates to shred it.
The Result: More of the mutant manual survives. Because more manuals survive, the cell builds more of the CFTR machine.
The Outcome: Even though the machine is still slightly broken (it's a truncated version), having more of them allows the cells to move salt and water better. In the lab tests, this restored some of the missing function in the cells.

What the Paper Proves (and What It Doesn't)

The researchers tested these keys in human lung cells that carry the W1282X mutation. Here is what they found:

More Instructions: The amount of CFTR RNA (the manual) went up.
More Machines: The amount of CFTR protein (the machine) went up.
Better Function: The cells moved chloride (salt) better, which is the main job of the CFTR machine.
No Skips: Unlike other treatments that try to skip the whole page, these tiny molecules worked without changing how the manual was read. They just stabilized the existing broken one.

Important Limitations:

It's not a cure yet: The paper calls this "proof-of-concept." It means the idea works in a lab, but the keys aren't perfect yet. They only partially restored function, and they aren't as powerful as the giant tools (ASOs) currently in development.
Not a permanent fix: These are small molecules, not gene editing. They don't change the DNA; they just temporarily help the cell deal with the typo.
Specific to this mutation: This approach targets the specific shape created by the W1282X mutation. It might not work for other types of Cystic Fibrosis mutations.

The Takeaway

This paper is like discovering that a broken instruction manual folds into a unique shape, and then inventing a tiny clip that holds that shape together just long enough for the factory to build a working machine. It opens a new door for treating Cystic Fibrosis by targeting the shape of the genetic instructions rather than just the words or the final product.

Technical Summary: Variant-Selective RNA-Targeting Small Molecules Partially Restore CFTR W1282X Function

Problem Statement
Cystic fibrosis (CF) caused by the p.W1282X nonsense variant in the CFTR gene presents a significant therapeutic challenge. This variant introduces a premature termination codon (PTC) that triggers nonsense-mediated mRNA decay (NMD), drastically reducing CFTR mRNA levels and limiting the expression of a truncated, yet partially functional, protein. Current small-molecule modulators, which target protein folding or channel gating, are largely ineffective against this Class I variant because the protein substrate is scarce. While antisense oligonucleotides (ASOs) have shown promise by inducing exon 23 skipping to stabilize mRNA, they face translational barriers regarding delivery and pharmacokinetics. There is a critical need for small-molecule therapies capable of targeting the mutant RNA directly to restore function without permanent genomic alteration.

Methodology
The study employed a structure-guided drug discovery pipeline targeting the RNA secondary structure of the CFTR W1282X transcript:

Structural Characterization: The authors utilized Selective 2′-Hydroxyl Acylation analyzed by Primer Extension (SHAPE) and SHAPE-Mutational Profiling (SHAPE-MaP) to compare the secondary structures of wild-type (WT) and W1282X CFTR RNA. These experiments were conducted both in vitro (using synthetic RNA) and in cellulo (in 16HBEge cells) to assess structural persistence in a physiological environment.
Virtual Screening: Based on SHAPE-derived constraints, 3D models of the W1282X RNA were generated. Using the Schrödinger molecular modeling suite, the researchers performed virtual screening against the ChemBridge Core Library (~211,000 compounds) to identify small molecules capable of binding a specific pocket adjacent to the variant site.
Biophysical Validation: Lead candidates were validated using Surface Plasmon Resonance (SPR) and Microscale Thermophoresis (MST) to confirm binding affinity and selectivity for the mutant RNA over WT RNA.
Chemical Synthesis and SAR: The lead compound, CTC20, and its structure-activity relationship (SAR)-guided analog, CTC24, were synthesized.
Functional and Molecular Assays: The compounds were tested in CFF-16HBEge-W1282X cells. Functional rescue was measured via automated transepithelial conductance (TECC-24) assays. Molecular mechanisms were assessed through RT-qPCR (mRNA abundance), Western blotting (protein expression and maturation), and RT-PCR (splicing analysis). ΔSHAPE-MaP was used to verify that the compounds induced localized structural changes specifically in the mutant transcript.

Key Contributions and Results

Discovery of a Variant-Specific RNA Conformation: The study demonstrated that the single-nucleotide G>A substitution in W1282X induces a distinct, localized hairpin conformation in exon 23. This structural rearrangement was observed in vitro and persisted within the cellular environment, differing significantly from the WT transcript despite similar global secondary structure topologies.
Identification of Selective Small Molecules: Virtual screening and biophysical validation identified CTC20 and CTC24 as compounds that selectively engage the W1282X-induced RNA conformation. MST analysis determined a dissociation constant ( $K_D$ ) of 19.81 µM for CTC20.
Structural Perturbation: ΔSHAPE-MaP analysis confirmed that CTC20 and CTC24 induce localized structural changes centered on the variant site. CTC24 demonstrated greater potency, inducing significant structural perturbations at 25 µM, a concentration where CTC20 showed no detectable effect. Crucially, neither compound significantly affected the corresponding region in WT RNA, confirming variant selectivity.
Functional Rescue: In W1282X-expressing cells, both compounds produced directional, dose-dependent increases in CFTR-mediated chloride conductance. While individual dose comparisons did not always reach statistical significance, the trend was consistent. CTC24 showed a statistically significant increase at 100 µM when combined with CFTR correctors (VX-661 and VX-445).
Mechanism of Action: The rescue mechanism was determined to be splicing-independent (unlike ASO-23AB). RT-qPCR and Western blot analyses revealed that the compounds partially stabilize the W1282X transcript against NMD-mediated degradation, leading to increased mRNA abundance (~1.5- to 1.8-fold) and subsequent increases in CFTR protein expression and maturation.

Significance and Claims
The paper establishes a proof-of-concept for a variant-selective, small-molecule RNA-targeting strategy for Class I cystic fibrosis variants. The authors claim that their work demonstrates:

Targetability: Disease-causing point mutations can create unique, druggable RNA structural elements that persist in cells.
Selectivity: Small molecules can be designed to selectively engage these mutant conformations over wild-type transcripts, offering a level of specificity difficult to achieve with protein-directed approaches.
Therapeutic Potential: By partially suppressing NMD and stabilizing the mutant transcript, small molecules can restore functional CFTR protein levels and chloride transport in cells harboring the W1282X variant.

The authors position this approach as a generalizable paradigm for targeting disease-associated RNA conformations in monogenic disorders. They acknowledge that the magnitude of rescue observed with these first-generation small molecules is modest compared to ASOs or NMD inhibitors (SMG1i) but emphasize that small molecules offer distinct advantages in pharmacokinetics, oral bioavailability, and the potential for iterative medicinal chemistry optimization to improve potency and selectivity. The study concludes that this strategy provides a foundation for developing precision therapeutics for CF patients currently unresponsive to existing modulators.